Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270357 | 0.89 | BRD4 (0.67) | BRD4 | |
| SCHEMBL13072390 | 0.84 | BRD4 (0.48) | BRD4SYKJAK2CYP3A4JAK1 | |
| Trifluoroacetic Acid SCHEMBL264264 | 0.81 | BRD4 (0.57) | BRD4SYK | |
| SCHEMBL271484 | 0.81 | BRD4 (0.52) | BRD4SYKJAK1JAK3AURKA | |
| SCHEMBL13637916 | 0.81 | BRD4 (0.69) | BRD4PKMYT1PDGFRBPDGFRA | |
| SCHEMBL13638218 | 0.80 | BRD4 (0.84) | BRD4 | |
| SCHEMBL13638219 | 0.80 | BRD4 (0.68) | BRD4SYKPKMYT1JAK1JAK3 | |
| SCHEMBL264902 | 0.79 | BRD4 (0.67) | BRD4SYKJAK2JAK1JAK3 | |
| SCHEMBL14536086 | 0.77 | JAK3 (0.63) | BRD4SYKJAK2JAK1JAK3 | |
| SCHEMBL760139 | 0.75 | BRD4 (0.61) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | BRD4 156/4885SYK 59/4885PKMYT1 1031/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | BRD4 142/4885SYK 281/4885PKMYT1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.